MedTrace Logo

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting

NCT02184416 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 554

Last updated 2026-02-27

No results posted yet for this study

Summary

This is an international, multi-centre, prospective (partly retrospective), observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated with sunitinib in first line and/or receiving axitinib in second line post sunitinib. The study is designed to enroll approximately 750 patients over the course of an enrollment period of approximately 36 months.

Conditions

  • Metastatic Renal Cell Carcinoma (mRCC)

Interventions

OTHER

observational

The study is non interventional. All drugs will be prescribed

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • Austria
  • Belgium
  • France
  • Greece
  • Italy
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02184416 on ClinicalTrials.gov